Hyperion’s Orphan Drug Ravicti Clears FDA; Postmarket Studies Required
This article was originally published in The Pink Sheet Daily
Executive Summary
Hyperion will launch the drug for treatment of urea cycle disorders in April, and the firm will need to plan a 10-year registry for patients.